Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.75 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.74 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | HPD | P32754 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254423 | 0.87 | SMPD1 (0.76) | MAOBMRGPRX4NR4A2SMPD1MAOA | |
| SCHEMBL30412034 | 0.87 | MAOB (0.73) | MAOBMRGPRX4NR4A2KMT2ASMPD1 | |
| SCHEMBL976424 | 0.87 | MAOB (0.73) | MAOBMRGPRX4NR4A2KMT2ASMPD1 | |
| SCHEMBL1122722 | 0.86 | MAOB (0.68) | MAOBMRGPRX4NR4A2KMT2ASMPD1 | |
| SCHEMBL28014191 | 0.86 | MAOB (0.75) | MAOBMRGPRX4NR4A2SMPD1HPD | |
| SCHEMBL10411878 | 0.85 | MRGPRX4 (0.77) | MAOBMRGPRX4NR4A2SMPD1MAOA | |
| SCHEMBL22480886 | 0.85 | MRGPRX4 (1.00) | MAOBMRGPRX4NR4A2MAOA | |
| SCHEMBL1122805 | 0.84 | MRGPRX4 (0.71) | MAOBMRGPRX4NR4A2KMT2ASMPD1 | |
| SCHEMBL1168262 | 0.84 | NR4A2 (1.00) | MAOBMRGPRX4NR4A2KMT2AHPD | |
| SCHEMBL25196508 | 0.84 | SMPD1 (0.73) | MAOBMRGPRX4NR4A2KMT2ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | MAOB 721/4885MRGPRX4 3754/4885NR4A2 969/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MAOB 1871/4885MRGPRX4 4239/4885NR4A2 679/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MAOB 1871/4885MRGPRX4 4239/4885NR4A2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.